Ligand ID: CXQ Drugbank ID: DB00245(Benzatropine) Indication:For use as an adjunct in the therapy of all forms of parkinsonism and also for use in the control of extrapyramidal disorders due to neuroleptic drugs. |
DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
---|---|---|---|---|---|---|---|---|---|---|
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 1x7q | HLA, A-11 (Homosapiens) | 4 / 5 | ALA A 135TYR A 123GLN A 141ILE A 142 | 1.55A | 22.2222.56 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 2acf | REPLICASEPOLYPROTEIN 1AB (SARS-COVTor2) | 4 / 6 | VAL D 198LEU D 322LEU D 308TYR D 191 | 1.32A | 20.8520.83 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 2ahm | REPLICASEPOLYPROTEIN 1AB,HEAVY CHAIN (SARSr-CoV) | 4 / 5 | ALA H 21TYR H 17GLN H 24ILE H 7 | 1.62A | 21.5621.80 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 2ajf | ACE2 (Homosapiens) | 4 / 5 | ARG B 559ALA B 384TYR B 381GLN B 388 | 1.33A | 18.9513.79 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 2ajf | ACE2 (Homosapiens) | 4 / 6 | VAL A 244LEU A 278LEU A 267TYR A 237 | 1.36A | 18.9513.79 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 2dd8 | SPIKE GLYCOPROTEIN (SARSr-CoV) | 4 / 6 | VAL S 369LEU S 374TYR S 367LEU S 499 | 1.16A | 23.1019.72 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 2fav | REPLICASEPOLYPROTEIN 1AB(PP1AB) (ORF1AB) (SARSr-CoV) | 4 / 6 | VAL C 17LEU C 141LEU C 127TYR C 10 | 1.36A | 20.8819.80 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 2fav | REPLICASEPOLYPROTEIN 1AB(PP1AB) (ORF1AB) (SARSr-CoV) | 4 / 5 | ALA B 18TYR B 10GLN B 151ILE A 132 | 1.56A | 20.8819.80 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 2fe8 | REPLICASEPOLYPROTEIN 1AB (SARSr-CoV) | 4 / 5 | ARG A 83ALA A 87TYR A 84ILE A 152 | 1.64A | 23.3118.93 | None BR A 319 (-4.0A)NoneNone | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 2ghv | SPIKE GLYCOPROTEIN (SARSr-CoV) | 4 / 6 | VAL E 369LEU E 377TYR E 367LEU E 499 | 1.07A | 22.3919.82 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 2ghw | ANTI-SCFV ANTIBODY,80R (Homosapiens) | 4 / 6 | VAL D 48LEU D 81LEU D 20LEU D 86 | 1.11A | 21.7918.92 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 2ozk | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARSr-CoV) | 4 / 6 | LEU B 299TYR B 237MET B 218LEU B 227 | 1.39A | 22.8321.17 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 2pwx | 3C-LIKE PROTEINASE (SARS-COVBJ01) | 4 / 6 | VAL A 42LEU A 87LEU A 89LEU A 58 | 1.41A | 21.1419.42 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 2rhb | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARSr-CoV) | 4 / 5 | ARG B 257ALA B 283GLN B 284ILE C 168 | 1.54A | 22.0821.17 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 2xyq | PUTATIVE 2'-O-METHYLTRANSFERASE (SARSr-CoV) | 4 / 6 | LEU A 89LEU A 95TYR A 47LEU A 126 | 1.41A | 20.5118.21 | NoneNoneSAH A1293 (-4.8A)None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 2xyr | PUTATIVE 2'-O-METHYLTRANSFERASE (SARSr-CoV) | 4 / 6 | LEU A 89LEU A 95TYR A 47LEU A 126 | 1.40A | 20.6218.09 | NoneNoneSFG A1298 (-4.6A)None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 3bgf | SPIKE PROTEIN S1 (SARSr-CoV) | 4 / 6 | VAL S 369LEU S 374TYR S 367LEU S 499 | 1.07A | 20.1919.34 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 3d0h | ACE2 (Pagumalarvata;Homosapiens;SARSr-CoV) | 4 / 6 | VAL B 244LEU B 278LEU B 267TYR B 237 | 1.42A | 19.4613.79 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 3d0i | ACE2 (Pagumalarvata;Homosapiens;SARSr-CoV) | 4 / 5 | ARG A 559ALA A 384TYR A 381GLN A 388 | 1.37A | 19.4613.79 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 3d62 | 3C-LIKE PROTEINASE (SARSr-CoV) | 4 / 6 | VAL A 42LEU A 87LEU A 89LEU A 58 | 1.41A | 21.0520.13 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 3f9h | 3C-LIKE PROTEINASE (SARSr-CoV) | 4 / 6 | VAL A 42LEU A 87LEU A 89LEU A 58 | 1.27A | 20.9319.42 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 3i6k | HLA, A-2 (Homosapiens) | 4 / 5 | ALA E 139TYR E 84GLN E 141ILE E 124 | 1.42A | 21.0121.80 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 3iwm | 3C-LIKE PROTEINASE (SARSr-CoV) | 4 / 6 | VAL D 42LEU D 87LEU D 89LEU D 58 | 1.00A | 20.9819.54 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 3mj5 | REPLICASEPOLYPROTEIN 1A (SARSr-CoV) | 4 / 5 | ARG B 83ALA B 87TYR B 84ILE B 152 | 1.61A | 23.2418.87 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 3r24 | 2'-O-METHYLTRANSFERASE (SARSr-CoV) | 4 / 6 | LEU A 89LEU A 95TYR A 47LEU A 126 | 1.41A | 19.5117.93 | NoneNoneSAM A 302 (-4.5A)None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 3sck | ACE2 (Pagumalarvata;Homosapiens;SARSr-CoV) | 4 / 5 | ARG A 559ALA A 384TYR A 381GLN A 388 | 1.30A | 19.4314.65 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 3scl | ACE2 (Pagumalarvata;Homosapiens;SARSr-CoV) | 5 / 6 | VAL A 209LEU A 95LEU A 91TYR A 215LEU A 560 | 1.66A | 19.4314.65 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 4hi3 | 3C-LIKE PROTEINASE (SARSr-CoV) | 4 / 6 | VAL A 42LEU A 87LEU A 89LEU A 58 | 1.40A | 20.6321.20 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 4rna | PAPAIN-LIKE PROTEASE (Humanbetacoronavirus2cEMC/2012) | 4 / 5 | ARG A 168ALA A 166TYR A 112ILE A 152 | 1.36A | 20.9920.49 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 5f22 | NSP8NSP7 (SARSr-CoV) | 4 / 6 | VAL A 21LEU A 18LEU B 100LEU A 65 | 1.15A | 18.5820.77 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 6 | VAL A 20LEU A 89LEU A 87MET A 162 | 1.59A | 19.8621.11 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 6 | VAL A 204LEU A 205LEU A 250LEU A 227 | 1.73A | 19.8621.11 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 6 | VAL A 86LEU A 87LEU A 89LEU A 27 | 1.80A | 19.8621.11 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 5tl6 | UBIQUITIN-LIKEPROTEIN ISG15 (Homosapiens) | 4 / 6 | VAL A 98LEU A 142TYR A 96LEU A 131 | 1.35A | 11.9314.71 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 5wrg | SPIKE GLYCOPROTEIN (SARSr-CoV) | 4 / 5 | ARG B 426ALA B 430TYR B 484GLN B 492 | 1.63A | 13.798.11 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 5x58 | SPIKE GLYCOPROTEIN (SARS-COVBJ01) | 4 / 6 | VAL B 369LEU B 374TYR B 367LEU B 499 | 1.18A | 14.018.80 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 5x5b | SPIKE GLYCOPROTEIN (SARS-COVBJ01) | 4 / 5 | ALA B 864TYR A 689GLN B 883ILE B 878 | 1.50A | 14.018.80 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 5xlr | SPIKE GLYCOPROTEIN (SARSr-CoV) | 4 / 6 | VAL B 369LEU B 374TYR B 367LEU B 499 | 1.38A | 13.798.11 | VAL B 369 ( 0.6A)LEU B 374 ( 0.6A)TYR B 367 ( 1.3A)LEU B 499 ( 0.6A) | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6acj | SPIKE GLYCOPROTEIN (SARSr-CoV) | 4 / 6 | VAL B 369LEU B 374TYR B 367LEU B 499 | 1.10A | 13.988.20 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6ack | ACE2 (Homosapiens) | 4 / 6 | VAL D 244LEU D 278LEU D 267TYR D 237 | 1.36A | 18.9114.65 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6crv | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 4 / 6 | VAL A 313LEU A 538LEU A 571LEU A 532 | 1.42A | 14.3311.80 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6crv | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 4 / 5 | ALA A 864TYR C 689GLN A 883ILE A 878 | 1.47A | 14.3311.80 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6crx | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 4 / 6 | VAL B 66LEU B 209TYR B 88LEU B 182 | 1.27A | 14.2511.35 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6cs1 | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 4 / 5 | ALA A 864TYR C 689GLN A 883ILE A 878 | 1.12A | 14.2511.35 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6cs2 | ACE2 (Homosapiens) | 4 / 6 | VAL D 244LEU D 278LEU D 267TYR D 237 | 1.40A | 18.7013.58 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6iex | MHC CLASS I ANTIGEN (Homosapiens) | 4 / 5 | ALA A 135TYR A 123GLN A 141ILE A 142 | 1.37A | 23.0824.21 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6jyt | HELICASE (SARSr-CoV) | 4 / 6 | VAL A 89LEU A 14LEU A 25LEU A 43 | 1.41A | 19.1612.89 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6m0j | ACE2 (Homosapiens) | 4 / 5 | ARG A 559ALA A 384TYR A 381GLN A 388 | 1.38A | 18.9114.65 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6m0j | SPIKE RECEPTORBINDING DOMAIN (SARS-CoV-2) | 4 / 5 | ALA E 475TYR E 489GLN E 474ILE E 472 | 1.54A | 20.7820.54 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6m17 | RECEPTOR BINDINGDOMAIN (SARS-CoV-2) | 4 / 6 | VAL F 382LEU F 387TYR F 380LEU F 513 | 1.37A | 20.7818.35 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6m17 | SODIUM-DEPENDENTNEUTRAL AMINO ACIDTRANSPORTER B(0)AT1 (Homosapiens) | 4 / 5 | ARG C 57ALA C 489TYR C 488ILE C 492 | 1.63A | 20.2913.96 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6m18 | ACE2 (Homosapiens) | 4 / 5 | ARG D 559ALA D 384TYR D 381GLN D 388 | 1.45A | 17.4411.69 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6m1d | ACE2 (Homosapiens) | 5 / 6 | VAL D 209LEU D 95LEU D 91TYR D 215LEU D 560 | 1.48A | 17.4411.69 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 6 | VAL C 296LEU C 253LEU C 250LEU C 208 | 1.46A | 21.47 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 4 / 6 | VAL A 296LEU A 253LEU A 250LEU A 208 | 1.47A | 21.47 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 6 | VAL A 820LEU A 819TYR A 831LEU A 602 | 1.49A | 15.59 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 6 | VAL A 182LEU A 127LEU A 131LEU A 146 | 1.29A | 15.59 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6m71 | NSP7NSP8 (SARS-CoV-2) | 4 / 6 | VAL C 16LEU C 13LEU D 95LEU C 60 | 1.10A | 17.41 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 6 | VAL A 472LEU A 469LEU A 630LEU A 636 | 1.53A | 15.59 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6m71 | NSP7 (SARS-CoV-2) | 4 / 6 | VAL C 16LEU C 17LEU C 55LEU C 60 | 1.37A | 17.41 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 6 | LEU A 178LEU A 146TYR A 122LEU A 131 | 1.47A | 15.59 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6m71 | NSP7NSP8 (SARS-CoV-2) | 4 / 6 | VAL C 66LEU C 59MET D 90LEU D 95 | 1.41A | 17.41 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 6 | VAL A 128LEU A 240TYR A 788LEU A 708 | 1.43A | 15.59 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6m71 | NSP7NSP8 (SARS-CoV-2) | 4 / 6 | VAL C 16LEU C 59LEU C 55LEU D 95 | 1.42A | 17.41 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6m71 | NSP7 (SARS-CoV-2) | 4 / 6 | VAL C 22LEU C 14LEU C 13LEU C 35 | 1.39A | 17.41 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6nb6 | SPIKE GLYCOPROTEIN (SARSr-CoV) | 4 / 5 | ALA B 864TYR C 689GLN B 883ILE B 878 | 1.37A | 13.9310.21 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6nb6 | SPIKE GLYCOPROTEIN (SARSr-CoV) | 4 / 6 | VAL A 369LEU A 374TYR A 367LEU A 499 | 1.13A | 13.9310.21 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6nur | NSP7NSP8 (SARSr-CoV) | 4 / 6 | VAL C 16LEU C 13LEU D 95LEU C 60 | 1.26A | 17.2618.63 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6nur | NSP12 (SARSr-CoV) | 4 / 6 | VAL A 182LEU A 127LEU A 131LEU A 146 | 1.24A | 15.8712.31 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 6 | VAL B 382LEU B 387TYR B 380LEU B 513 | 1.14A | 12.979.88 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | ALA B 419TYR B 423GLN B 409ILE B 402 | 1.27A | 12.979.88 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6vw1 | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | ALA F 475TYR F 489GLN F 474ILE F 472 | 1.53A | 23.4017.57 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6vw1 | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 6 | VAL E 382LEU E 387TYR E 380LEU E 513 | 1.13A | 23.4017.57 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6vxs | NSP3 (SARS-CoV-2) | 4 / 6 | LEU A 75LEU A 43TYR B 42LEU A 93 | 1.55A | SO4 A 201 (-4.1A)NoneNoneNone | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6vxs | NSP3 (SARS-CoV-2) | 4 / 6 | VAL B 16LEU B 140LEU B 126TYR B 9 | 1.44A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6vxs | NSP3 (SARS-CoV-2) | 4 / 6 | VAL A 16LEU A 140LEU A 126TYR A 9 | 1.43A | None | |||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6vxx | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | ARG A 905ALA A 903GLN A 901ILE A 896 | 1.64A | 13.819.74 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6vyb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 6 | VAL C 382LEU C 387TYR C 380LEU C 513 | 1.06A | 13.819.74 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w02 | NSP3 (SARS-CoV-2) | 4 / 6 | VAL B 16LEU B 140LEU B 126TYR B 9 | 1.35A | 21.9221.99 | NoneNoneAPR B 201 (-4.8A)None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w41 | CR3022 FAB HEAVYCHAIN (Homosapiens) | 4 / 6 | VAL H 211LEU H 138LEU H 189LEU H 159 | 1.71A | 18.8719.54 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w41 | CR3022 FAB LIGHTCHAINSPIKE PROTEIN S1 (Homosapiens;SARS-CoV-2) | 4 / 6 | LEU C 390LEU C 387TYR L 32LEU C 517 | 1.73A | 20.0019.65 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w41 | SPIKE PROTEIN S1 (SARS-CoV-2) | 4 / 5 | ALA C 475TYR C 489GLN C 474ILE C 472 | 1.52A | 20.0019.65 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w41 | SPIKE PROTEIN S1 (SARS-CoV-2) | 4 / 5 | ALA C 419TYR C 423GLN C 409ILE C 402 | 1.69A | 20.0019.65 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w41 | CR3022 FAB HEAVYCHAIN (Homosapiens) | 4 / 5 | ALA H 78TYR H 79GLN H 6ILE H 20 | 1.71A | 18.8719.54 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w4h | NSP16 (SARS-CoV-2) | 4 / 6 | LEU A6887LEU A6893TYR A6845LEU A6924 | 1.38A | 20.2319.16 | NoneNoneSAM A7102 (-4.5A)None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | VAL A6882LEU A6893TYR A6845LEU A6924 | 1.80A | 17.9322.22 | NoneNoneSAM A7104 (-4.6A)None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | LEU A6887LEU A6893TYR A6845LEU A6924 | 1.40A | 17.9322.22 | NoneNoneSAM A7104 (-4.6A)None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | LEU A6981LEU A6978TYR A6950LEU A6959 | 1.65A | 17.9322.22 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | VAL A6859LEU A7050LEU A6852LEU A6883 | 1.73A | 17.9322.22 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | VAL A6865LEU A6887LEU A7050LEU A6848 | 1.77A | 17.9322.22 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 6 | VAL A 16LEU A 12TYR A 113LEU A 164 | 1.70A | 19.0921.35 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 6 | VAL B 151LEU B 122LEU B 93TYR B 113 | 1.79A | 19.0921.35 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 6 | VAL A 16LEU A 153LEU A 140LEU A 127 | 1.70A | 19.0921.35 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 6 | VAL A 144LEU A 140LEU A 153LEU A 10 | 1.45A | 19.0921.35 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 6 | VAL B 16LEU B 12TYR B 113LEU B 164 | 1.68A | 19.0921.35 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 6 | VAL A 16LEU A 140LEU A 126TYR A 9 | 1.39A | 19.0921.35 | NoneNoneAMP A 201 ( 4.4A)None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 6 | VAL B 151LEU B 153LEU B 140LEU B 127 | 1.62A | 19.0921.35 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 6 | VAL B 16LEU B 140LEU B 126TYR B 9 | 1.37A | 19.0921.35 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 6 | VAL B 16LEU B 153LEU B 140LEU B 127 | 1.71A | 19.0921.35 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 6 | VAL A 151LEU A 153LEU A 140LEU A 127 | 1.66A | 19.0921.35 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 6 | VAL B 144LEU B 140LEU B 153LEU B 10 | 1.50A | 19.0921.35 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 6 | VAL B 144LEU B 12LEU B 164TYR B 113 | 1.70A | 19.0921.35 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 6 | LEU B 140LEU B 12TYR B 161LEU B 153 | 1.69A | 19.0921.35 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 6 | VAL A6865LEU A6887LEU A7050LEU A6848 | 1.75A | 19.3724.18 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 6 | LEU A6887LEU A6893TYR A6845LEU A6924 | 1.38A | 19.3724.18 | NoneNoneSAM A7102 ( 4.5A)None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 6 | VAL C6865LEU C6887LEU C7050LEU C6848 | 1.75A | 19.3724.18 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 6 | VAL C6859LEU C7050LEU C6852LEU C6883 | 1.71A | 19.3724.18 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 6 | VAL C6882LEU C6893TYR C6845LEU C6924 | 1.80A | 19.3724.18 | NoneNoneSAM C7105 ( 4.5A)None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 6 | LEU C6981LEU C6978TYR C6950LEU C6959 | 1.68A | 19.3724.18 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 6 | VAL A6859LEU A7050LEU A6852LEU A6883 | 1.72A | 19.3724.18 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 6 | LEU C6887LEU C6893TYR C6845LEU C6924 | 1.38A | 19.3724.18 | NoneNoneSAM C7105 ( 4.5A)None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 6 | LEU A6981LEU A6978TYR A6950LEU A6959 | 1.67A | 19.3724.18 | NoneNoneFMT A7109 ( 4.9A)None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 4 / 5 | ARG B 82ALA B 86TYR B 83ILE B 151 | 1.63A | 22.7017.13 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 4 / 6 | LEU C 120LEU C 125TYR C 137LEU C 132 | 1.53A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 4 / 6 | LEU A 120LEU A 125TYR A 137LEU A 132 | 1.46A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6w9q | 3C-LIKE PROTEINASEPEPTIDE, NSP9 FUSION (SARS-CoV-2) | 4 / 6 | VAL A 110LEU A 106LEU A -8LEU A 29 | 1.43A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6wcf | NSP3 (SARS-CoV-2) | 4 / 6 | VAL A 16LEU A 140LEU A 126TYR A 9 | 1.37A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6wen | NSP3 (SARS-CoV-2) | 4 / 6 | VAL A 16LEU A 140LEU A 126TYR A 9 | 1.35A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6wey | NSP3 (SARS-CoV-2) | 4 / 6 | VAL A 220LEU A 344LEU A 330TYR A 213 | 1.39A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6wiq | NSP7NSP8 (SARS-CoV-2) | 4 / 6 | VAL A 16LEU A 13LEU B 95LEU A 60 | 1.23A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6wiq | NSP7NSP8 (SARS-CoV-2) | 4 / 6 | VAL A 16LEU B 91LEU A 71LEU A 60 | 1.41A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6wiq | NSP7NSP8 (SARS-CoV-2) | 4 / 6 | VAL A 66LEU A 59LEU A 17MET B 87 | 1.34A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | LEU C6887LEU C6893TYR C6845LEU C6924 | 1.38A | NoneNoneSAH C7102 (-4.6A)None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | LEU A6887LEU A6893TYR A6845LEU A6924 | 1.38A | NoneNoneSAH A7102 (-4.6A)None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 6 | VAL D 72LEU D 161LEU D 159LEU D 64 | 1.56A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 6 | LEU C6887LEU C6893TYR C6845LEU C6924 | 1.38A | NoneNoneSFG C7103 ( 4.5A)None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 6 | LEU A6887LEU A6893TYR A6845LEU A6924 | 1.38A | NoneNoneSFG A7103 ( 4.6A)None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 4 / 6 | VAL A 295LEU A 255LEU A 266LEU A 246 | 1.55A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 4 / 6 | VAL B 295LEU B 255LEU B 266LEU B 246 | 1.52A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | VAL C 16LEU C 140LEU C 126TYR C 9 | 1.39A | NoneNoneAPR C 201 (-4.9A)None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | VAL B 16LEU B 140LEU B 126TYR B 9 | 1.39A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | VAL D 16LEU D 140LEU D 126TYR D 9 | 1.38A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | VAL A 16LEU A 140LEU A 126TYR A 9 | 1.37A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | LEU A6887LEU A6893TYR A6845LEU A6924 | 1.39A | NoneNoneSAH A7101 (-4.5A)None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 6 | VAL C 66LEU C 59LEU C 17MET D 87 | 1.44A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6wqd | NSP7 (SARS-CoV-2) | 4 / 6 | VAL C 16LEU C 59LEU C 56LEU C 71 | 0.98A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6wqd | NSP7 (SARS-CoV-2) | 4 / 6 | VAL A 16LEU A 17LEU A 55LEU A 60 | 1.55A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6wqd | NSP7 (SARS-CoV-2) | 4 / 6 | VAL A 16LEU A 59LEU A 56LEU A 71 | 1.00A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6wqd | NSP7 (SARS-CoV-2) | 4 / 6 | VAL C 22LEU C 14LEU C 13LEU C 35 | 1.51A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6wqd | NSP7 (SARS-CoV-2) | 4 / 6 | VAL C 16LEU C 17LEU C 55LEU C 60 | 1.56A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 6 | VAL A 66LEU A 59LEU A 17MET B 87 | 1.46A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 6 | VAL C 16LEU C 13LEU D 95LEU C 60 | 1.21A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 6 | VAL A 16LEU A 13LEU B 95LEU A 60 | 1.23A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | LEU A 87LEU A 89MET A 162LEU A 27 | 1.80A | 19.8621.62 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | VAL A 204LEU A 205LEU A 250LEU A 227 | 1.72A | 19.8621.62 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | VAL A 86LEU A 87LEU A 89LEU A 27 | 1.79A | 19.8621.62 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | VAL A 20LEU A 89LEU A 87MET A 162 | 1.58A | 19.8621.62 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 6 | VAL A 16LEU A 13LEU B 95LEU A 60 | 1.27A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 6 | VAL C 16LEU C 13LEU D 95LEU C 60 | 1.19A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 6 | VAL A 22LEU A 14LEU A 13LEU A 35 | 1.53A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 6 | VAL A 66LEU A 59LEU A 17MET B 87 | 1.54A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 6 | VAL A 66LEU B 91LEU B 95LEU A 55 | 1.54A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 6 | VAL C 22LEU C 14LEU C 13LEU C 35 | 1.54A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 6 | VAL C 16LEU C 59LEU C 56LEU C 71 | 1.01A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 6 | VAL C 16LEU C 17LEU C 55LEU C 60 | 1.54A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 6 | VAL A 16LEU A 59LEU A 56LEU A 71 | 1.07A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 6 | VAL C 53LEU C 56TYR D 149LEU C 71 | 1.55A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 6 | VAL C 66LEU C 59LEU C 17MET D 87 | 1.45A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 6 | VAL C 16LEU C 59LEU C 55LEU D 95 | 1.45A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 6 | VAL A 53LEU A 56TYR B 149LEU A 71 | 1.53A | None | |||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yla | HEAVY CHAIN (Homosapiens) | 4 / 5 | ALA B 79TYR B 80GLN B 6ILE B 20 | 1.77A | 20.4118.88 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | ALA E 419TYR E 423GLN E 409ILE E 402 | 1.73A | 20.6621.30 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | ALA E 475TYR E 489GLN E 474ILE E 472 | 1.71A | 20.6621.30 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | ALA A 475TYR A 489GLN A 474ILE A 472 | 1.56A | 20.6621.30 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yla | HEAVY CHAIN (Homosapiens) | 4 / 5 | ALA H 79TYR H 80GLN H 6ILE H 20 | 1.71A | 20.4118.88 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | ALA A 419TYR A 423GLN A 409ILE A 402 | 1.72A | 20.6621.30 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6ym0 | HEAVY CHAIN (Homosapiens) | 4 / 5 | ALA H 79TYR H 80GLN H 6ILE H 20 | 1.66A | 20.5819.21 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6ym0 | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | ALA E 475TYR E 489GLN E 474ILE E 472 | 1.75A | 20.6621.30 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6ym0 | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | ALA E 419TYR E 423GLN E 409ILE E 402 | 1.74A | 20.6621.30 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | VAL A 296LEU A 253LEU A 250LEU A 208 | 1.44A | None | |||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | ALA A 475TYR A 489GLN A 474ILE A 472 | 1.71A | 20.4518.05 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | ALA E 419TYR E 423GLN E 409ILE E 402 | 1.73A | 20.4518.05 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | ALA E 475TYR E 489GLN E 474ILE E 472 | 1.71A | 20.4518.05 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yor | IGG H CHAIN (Homosapiens) | 4 / 5 | ALA B 79TYR B 80GLN B 6ILE B 20 | 1.71A | 20.4118.88 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | ALA A 419TYR A 423GLN A 409ILE A 402 | 1.73A | 20.4518.05 | None | ||
![]() | 6F6S_A_CXQA507_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yor | IGG H CHAIN (Homosapiens) | 4 / 5 | ALA H 79TYR H 80GLN H 6ILE H 20 | 1.71A | 20.4118.88 | None | ||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | VAL A 296LEU A 253LEU A 250LEU A 208 | 1.45A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 6 | VAL C 16LEU C 140LEU C 126TYR C 9 | 1.39A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 6 | VAL E 16LEU E 140LEU E 126TYR E 9 | 1.40A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 6 | VAL B 16LEU B 140LEU B 126TYR B 9 | 1.41A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 6 | VAL A 16LEU A 140LEU A 126TYR A 9 | 1.41A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 6 | VAL D 16LEU D 140LEU D 126TYR D 9 | 1.41A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 6 | VAL D 16LEU D 140LEU D 126TYR D 9 | 1.41A | NoneNoneAPR D 201 (-4.5A)None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 6 | VAL C 16LEU C 140LEU C 126TYR C 9 | 1.39A | NoneNoneAPR C 201 (-4.8A)EDO C 204 ( 4.9A) | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 6 | VAL A 16LEU A 140LEU A 126TYR A 9 | 1.42A | NoneNoneAPR A 201 (-4.8A)EDO A 202 (-4.6A) | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 6 | VAL E 16LEU E 140LEU E 126TYR E 9 | 1.38A | NoneNoneAPR E 201 (-4.7A)None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 6 | VAL B 16LEU B 140LEU B 126TYR B 9 | 1.42A | NoneNoneAPR B 201 (-4.7A)None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 6 | VAL C 16LEU C 140LEU C 126TYR C 9 | 1.36A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 6 | VAL B 16LEU B 140LEU B 126TYR B 9 | 1.38A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 6 | VAL A 16LEU A 140LEU A 126TYR A 9 | 1.40A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 7btf | NSP12 (SARS-CoV-2) | 4 / 6 | VAL A 472LEU A 469LEU A 630LEU A 636 | 1.56A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 7btf | NSP12 (SARS-CoV-2) | 4 / 6 | VAL A 128LEU A 240TYR A 788LEU A 708 | 1.43A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 7btf | NSP7NSP8 (SARS-CoV-2) | 4 / 6 | VAL C 16LEU C 13LEU D 95LEU C 60 | 1.12A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 7btf | NSP12 (SARS-CoV-2) | 4 / 6 | VAL A 820LEU A 819TYR A 831LEU A 602 | 1.55A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 7btf | NSP7NSP8 (SARS-CoV-2) | 4 / 6 | VAL C 16LEU C 59LEU C 55LEU D 95 | 1.35A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 7btf | NSP7 (SARS-CoV-2) | 4 / 6 | VAL C 16LEU C 17LEU C 55LEU C 60 | 1.31A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 7btf | NSP12 (SARS-CoV-2) | 4 / 6 | VAL A 182LEU A 127LEU A 131LEU A 146 | 1.33A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 7btf | NSP12 (SARS-CoV-2) | 4 / 6 | LEU A 178LEU A 146TYR A 122LEU A 131 | 1.41A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 6 | VAL A 820LEU A 819TYR A 831LEU A 602 | 1.53A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 7bv1 | NSP7NSP8 (SARS-CoV-2) | 4 / 6 | VAL C 16LEU C 13LEU D 95LEU C 60 | 1.26A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 6 | VAL A 182LEU A 127LEU A 131LEU A 146 | 1.23A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 6 | VAL A 128LEU A 240TYR A 788LEU A 708 | 1.41A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 7bv1 | NSP7NSP8 (SARS-CoV-2) | 4 / 6 | VAL C 16LEU C 59LEU C 55LEU D 95 | 1.36A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 7bv1 | NSP12NSP8 (SARS-CoV-2) | 4 / 6 | VAL A 338LEU B 95LEU B 98LEU B 91 | 1.55A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 7bv1 | NSP7 (SARS-CoV-2) | 4 / 6 | VAL C 22LEU C 14LEU C 13LEU C 35 | 1.43A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 6 | LEU A 178LEU A 146TYR A 122LEU A 131 | 1.46A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 6 | VAL A 182LEU A 127LEU A 131LEU A 146 | 1.22A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 6 | VAL A 128LEU A 240TYR A 788LEU A 708 | 1.49A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 7bv2 | NSP7 (SARS-CoV-2) | 4 / 6 | VAL C 22LEU C 14LEU C 13LEU C 35 | 1.56A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 6 | LEU A 178LEU A 146TYR A 122LEU A 131 | 1.47A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 6 | VAL A 820LEU A 819TYR A 831LEU A 602 | 1.52A | None | |||
![]() | 6F6S_B_CXQB705_1 (ENVELOPEGLYCOPROTEIN,ENVELOPE GLYCOPROTEIN,GP1ENVELOPEGLYCOPROTEIN) | 7bv2 | NSP12NSP8 (SARS-CoV-2) | 4 / 6 | VAL A 338LEU B 95LEU B 98LEU B 91 | 1.52A | None |